Columbus Venture Partners

How we do it

COLUMBUS VENTURE PARTNERS, S G E I C , S A U enhances the value of the most promising projects arising from renowned Spanish research institutions by guaranteeing that proper work takes places and ensuring the scientific, technological and commercial potential is understood before large capital is invested

Integra Therapeutics acquires CRISPR licence from CIC nanoGUNE

2 6 billion-year-old ancestors of the CRISPR gene-editing tool are resurrected An international study led by Spanish scientists has deciphered the origin

Artax Biopharma Expands Company’s Scientific Advisory Board

Company Welcomes James G Krueger, M D , Ph D , and Ajay Nirula, M D , Ph D , Both Experts in T-Cell-Mediated Diseases Cambridge, MA, November 15,

AURA announces the design of a global phase 3 trial of Bel-Sar

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap